Christian B. Dinneen-Long
Conseiller Juridique Général chez GLYCOMIMETICS, INC.
Postes actifs de Christian B. Dinneen-Long
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| GLYCOMIMETICS, INC. | Conseiller Juridique Général | 29/04/2019 | - |
| Secrétaire Général | 29/04/2019 | - |
Historique de carrière de Christian B. Dinneen-Long
Anciens postes connus de Christian B. Dinneen-Long
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| EMERGENT BIOSOLUTIONS INC. | Conseiller Juridique Général | - | - |
Guilford Pharmaceuticals, Inc.
 Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Conseiller Juridique Général | - | - |
| Medimmune, Inc. | Conseiller Juridique Général | - | - |
Formation de Christian B. Dinneen-Long
| Chicago-Kent College of Law | Graduate Degree |
| University of Wisconsin | Undergraduate Degree |
Statistiques
Internationale
| Etats-Unis | 7 |
Opérationnelle
| General Counsel | 4 |
| Corporate Secretary | 1 |
| Graduate Degree | 1 |
Sectorielle
| Health Technology | 5 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| GLYCOMIMETICS, INC. | Health Technology |
| EMERGENT BIOSOLUTIONS INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
| Medimmune, Inc. | Health Technology |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Health Technology |
- Bourse
- Insiders
- Christian B. Dinneen-Long
- Expérience